The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $9,247,170 in first-year total cost, median $4,623,585.
Most frequent study sections
- Special Emphasis Panel[ZAG1 ZIJ-G (J3)]1
- Special Emphasis Panel[ZAG1 ZIJ-G (O1)]1
Most frequent institutions
- AGENEBIO, INC.1
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Metformin in Alzheimer's dementia Prevention (MAP)1R01AG062624-01 | LUCHSINGER, JOSE ALEJANDRO | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $4,296,110 | ZAG1 |
| 2018 | A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease1R01AG061091-01 | MOHS, RICHARD CHARLES | AGENEBIO, INC., MD | $4,951,060 | ZAG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.